



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231 on September 13, 2002.

SUBMISSION OF SEQUENCE LISTING  
UNDER 37 CFR §§1.821-1.825  
Patent Application  
Docket No. GJE-88  
Serial No. 10/070,568

David Saliwanchik  
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|            |   |                                      |
|------------|---|--------------------------------------|
| Applicants | : | You-Min Feng, You-Shang Zhang        |
| Serial No. | : | 10/070,568                           |
| Filed      | : | March 8, 2002                        |
| Conf. No.  | : | 7193                                 |
| For        | : | Monomeric Analogues of Human Insulin |

Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

## SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825

Sir:

Transmitted herewith is a replacement Sequence Listing Under 37 CFR §§1.821 through 1.825 for the above-identified patent application. A Notification of Defective Response Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) was received from the Patent and Trademark Office, and a copy of the Notification is enclosed herewith.

The Sequence Listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRS/la

Attachments: Sequence listing on paper and computer readable format containing the same information; Amendment Under 37 CFR §1.825(a) through (c); copy of Notification of Defective Response.